Use of bisphenolic compounds to treat type ii diabetes

Details Use of bisphenolic compounds to treat type ii diabetes Use of bisphenolic compounds to treat type ii diabetes

A - Human Necessities

61

K

A61K 31/05 (2006.01)

Patent

CA 2268874

This invention is directed to methods for treatment of non-insulin-dependent diabetes mellitus, for reducing blood glucose levels, or hyperglycemia. The methods entail administering to a mammal in need of such treatment a therapeutically effective amount of a composition whose active ingredient consists essentially of a compound of structure (I) or a pharmaceutically acceptable salt thereof. In the compound R and R' are independently H or a C1- C20 alkyl or C2-C20 alkenyl group which may be substituted or unsubstituted. Alternatively, R and R' are such that together a cycloalkyl or cycloalkenyl ring is formed. In the chain linking the two phenolic derivatives each of (C(R)=C(R')) or (C(R)(R')) are the same or different. A and A' are independently C2-C20 acylamino, C2-C20 acyloxy, C2-C20 alcanoyl, C2-C20 alkoxycarbonyl, C1-C20 alkoxyl, C1-C20 alkylamino, C2-C20 alkyl carboxyl, amino, C2-C20 carbalkoxyl, carboxyl, cyano, halo, hydroxy. B and B' are independently H, C2-C20 alkanoyl, C3-C20 alkenoyl, C2-C20 alkenyl, C2-C20 alkoxycarbonyl, C1-C20 alkyl, aroyl, aralkanoyl, C2-C20 carbamoyl, or phosphate. The invention is also directed to methods of treatment using a bisphenolic compound in conjunction with another hypoglycemic or hypolipidemic agent.

L'invention concerne des procédés servant à traiter le diabète sucré non insulinodépendant, en limitant les niveaux de glucose dans le sang ou hyperglycémie. Ces procédés consiste à administrer à un mammifère une quantité efficace sur le plan thérapeutique d'une composition dont l'ingrédient actif est constitué essentiellement par un composé présentant la structure (I) ou un de ses sels acceptable sur le plan pharmaceutique: Dans ce composé, R et R' représente indépendamment H ou un groupe alkyle C1-C20 ou alkényle C2-C20 pouvant être substitué ou insubstitué. Dans un autre aspect, R et R' sont à même de constituer ensemble une chaîne cycloalkyle ou cycloalkényle. Dans la chaîne reliant les deux dérivés phénoliques, chacun de (C(R)=C(R')) ou (C(R)(R')) est semblable ou différent. A et A' représentent indépendamment acylamino C2-C20, acyloxy C2-C20, alkynoyle C2-C20, alkoxycarbonyle C2-C20, alkoxyle C1-C20, aminoalkyle C1-C20, carboxyalkyle C2-C20, amino, carbalkoxyle C2-C20, carboxyle, cyano, halo, hydroxy. B et B' représentent indépendamment H, alkanoyle C2-C20, alkénoyle C3-C20, alkényle C2-C20, alkoxycarbonyle C2-C20, alkyle C1-C20, aroyle, aralkanoyle, carbamoyle C2-C20 ou phosphate. L'invention concerne également des procédés de traitement au moyen d'un composé bisphénolique combiné à un autre agent hypoglycémique ou hypolipidémique.

Affiliated with

Also associated with

Rating

Use of bisphenolic compounds to treat type ii diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of bisphenolic compounds to treat type ii diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bisphenolic compounds to treat type ii diabetes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1724539